MULTIDRUG RESISTANCE PROTEIN: P-GLYCOPROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 261

209. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-
glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
210. Chelule PK, Gordon M, Palanee T, Page T, Mosam A, Derm FC, Coovadia HM, Cassol S.
2003. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations
in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 74:195-196.
211. Chowbay B, Li HH, David M, Cheung YB, Lee EJD. 2005. Meta-analysis of the influ-
ence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene
expression. Br J Clin Pharmacol 60:159-171.
212. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. 2004. Polymorphisms in the
multidrug resistance-1 ( MDR1 ) gene influence the response to atorvastatin treatment in
a gender-specific manner. Am J Cardiol 93:1046-1050.
213. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K. 1989.
P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries
Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun
162:224-231.
214. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C, Sikic BI. 1997.
Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered pheno-
type, and resistance to cyclosporins. J Biol Chem 272:5974-5982.
215. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. 2002. Functional characterization of coding
polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol
Pharmacol 62:1-6.
216. Morita N, Yasumori T, Nakayama K. 2003. Human MDR1 polymorphism: G2677T/A and
C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843-1852.
217. Woodahl EL, Yang ZP, Bui T, Shen DD, Ho RJY. 2004. Multidrug resistance gene G1199A
polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther
310:1199-1207.
218. Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng WP, Nicks A, Tsang
M, Shows D, Morrissey P, Viney JL. 2005. Dual infection with Helicobacter bilis and
Helicobacter hepaticus in P-glycoprotein-deficient mdr1a

− −

/ mice results in colitis that

progresses to dysplasia. Am J Pathol 166:1793-1806.
219. Brant SR, Panhuysen CIM, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang LL,
Swanson E, Datta LW, Moran T, et al. 2003. MDR1 Ala893 polymorphism is associated
with inflammatory bowel disease. Am J Hum Genet 73:1282-1292.
220. Schwab M, Schaffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth
H, Schoelmerich J, Gregor M, et al. 2003. Association between the C3435T MDR1 gene
polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124:26-33.
221. Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, Telenti A, Swiss HIV
CS. 2004. MDR1 genetic polymorphism does not modify either cell permissiveness to
HIV-1 or disease progression before treatment. J Infect Dis 189:583-586.
222. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer
H, Opravil M, Pantaleo G, et al. 2002. Response to antiretroviral treatment in HIV-
1-infected individuals with allelic variants of the multidrug resistance transporter 1: a
pharmacogenetics study. Lancet 359:30-36.
223. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan
PR. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial
antiretroviral therapy response. AIDS 17:201-208.